Background
==========

Breast cancer is the most frequent malignant neoplasm in women worldwide \[[@B1]\]. In the past, its incidence and mortality in Central and Eastern European countries were significantly lower than in Western Europe. Yet recent changes in reproductive behaviour of women accompanied by significant demographic changes led to a sharp increase in breast cancer incidence in Eastern European countries including the Czech Republic \[[@B2]\]. Stabilisation of mortality from breast cancer can only be achieved through high quality screening associated with adequate treatment of detected tumours \[[@B3]\]. Efficacy of breast cancer screening by mammography in preventing breast cancer deaths was demonstrated in randomised controlled trials. Meta-analysis of Swedish trials showed breast cancer mortality reduction of 29% among women aged 50-69 years \[[@B4]\]. Recent meta-analyses stated mortality reduction to be 15% \[[@B5]\], however, greater protective effect seem to be present in women between 60-69 years \[[@B6]\]. Screening programmes were implemented in many countries worldwide \[[@B7],[@B8]\]. The effect indeed persists in real populations: breast cancer mortality decreased by 16% to 36% in populations invited to screening and women attending at least one screening examination could decrease their risk of death from breast cancer by 24% to 48% \[[@B9]\]. On the other hand, there are also adverse effects associated with breast cancer screening by mammography. Namely these include radiation exposure, pain during mammography, anxiety responses from screening, false-positive and false-negative results, and overdiagnosis \[[@B6]\]. However, there is convincing evidence that, in certain age groups, benefits of mammography screening outweigh its risk. This led to recommendations for screening in United States \[[@B10]\] and Europe \[[@B11]\].

To obtain projected benefits and minimise negative outcomes, the programmes should be implemented with an organised, population-based approach, with quality assurance at all appropriate levels, and in accordance with European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis \[[@B11],[@B12]\]. The policy of a screening effort should be documented in a law or an official regulation to qualify as a screening programme \[[@B8]\]. IARC Handbooks of cancer prevention \[[@B13]\] state six characteristics of an organised screening programme: a policy specifying target population, screening method and interval; a defined target population; a team responsible for overseeing screening centres; a decision structure and responsibility for healthcare management; a quality assurance system utilizing relevant data; and monitoring of cancer occurrence in the target population. The highest level of programme organisation, population-based screening, requires that all persons eligible for screening are identified and personally invited to attend a screening examination in each round of screening \[[@B8]\].

The objective of this article is to summarize the implementation and results of the Czech breast cancer screening programme (CBCSP) since 2002. The evaluation of CBCSP is based on a multi-source information system including the monitoring of population cancer burden and early performance indicators of the screening programme. Favourable values of screening performance measures are necessary to have a significant effect on cancer mortality in the future \[[@B14]\]. Therefore, we describe the results of transformation from no-programme opportunistic screening to a non-population based yet highly organised programme by comparison of measured indicators to international guideline targets and published results. To our knowledge, this is one of the first reports from a new EU member state. Compared to previous papers \[[@B15]-[@B17]\], this article adds new results on long-term continuous quality improvement after the programme initiation.

Methods
=======

The Czech Breast Cancer Screening Programme
-------------------------------------------

In the late 1990s, mammography was performed at more than 130 facilities and screening examinations were claimed as diagnostic. In 2002 an accreditation programme was launched by a directive of the Czech Ministry of Health with accreditation criteria based on the European Guidelines \[[@B11]\]. The programme is administered by the Breast Cancer Screening Committee at the Ministry of Health. The centres are overseen by the Expert Committee on Breast Imaging (*Komise odborníků pro mamární diagnostiku*).

The CBCSP is a nationwide organized programme, currently performed at 67 regularly monitored accredited centres. The target population was defined as women aged 45-69 years. Since 2010 there is no upper age limit, therefore all women from 45 years of age can attend a biennial mammography screening covered by health insurance. Women are referred to screening mammography by their general practitioners (GPs) or gynaecologists on the basis of preventive check-ups, as there is no established centralised system of direct invitation yet. Women outside the target population (over 40 years of age) can undergo screening mammography (upon direct payment of entire cost of the screening examination) and are therefore included in aggregated statistics.

Mammography is performed in two-views (craniocaudal, mediolateral oblique), independent double reading with consensus is recommended. Both screen-film and digital mammography systems are present. Screening centres also act as breast assessment units, necessary further assessment of the findings (magnification, spot mammography, breast ultrasound, etc.) is provided during the screening visit at the centre (one-day diagnostics). Recall to the screening centre is usually employed in case of a double reading discrepancy or for invasive examinations, including core-cut biopsy (majority performed within one week after screening). For reporting of screening and additional imaging results, the BI-RADS system \[[@B18]\] is used and for the evaluation of breast density, typology according to Tabar was included \[[@B19]\]. All of the centres provide core-cut biopsy, special methods (MR mammography and vacuum biopsy) are provided at a narrower network of specialized centres.

Screening programme data are annually consolidated from local databases of screening centres, and are subsequently stored in a secured central database - the Czech Breast Cancer Screening Registry (Figure [1](#F1){ref-type="fig"}). Official results containing a description of the screening process and performance monitoring are published annually. Feedback for screening centres is provided using annual reporting of performance indicators.

![**Structure of a patient record in the Czech Breast Cancer Screening Registry**.](1471-2458-11-288-1){#F1}

Czech National Cancer Registry
------------------------------

The Czech National Cancer Registry (CNCR) was established in 1976. With verified 100% coverage, it contains information on the cancer diagnosis, treatment and survival of all Czech cancer patients. A comprehensive overview of cancer epidemiology in the Czech Republic is available on-line at <http://www.svod.cz>\[[@B20]\].

Claims data from healthcare payers
----------------------------------

The costs of biennial screening mammography in women from the screening target population are reimbursed by public health insurance in the Czech Republic. Therefore, claims data on mammography are available in data warehouses of healthcare payers provided via centralized exports by the Czech National Reference Centre. These administrative records allow for a description of the utilisation of diagnostic and screening mammography in the Czech female population and to monitor the prevalence of opportunistic screening outside the organised programme.

Data analysis
-------------

Population-based data of CNCR was analysed using standard methods \[[@B21]\] to detect trends in incidence and mortality. The performance of the programme was assessed using the standard set of performance indicators introduced in European Guidelines \[[@B11]\]. The coverage of the target population by screening examination was computed as a ratio between the number of examinations in women aged 45-69 years in previous 24 months and the number of women aged 45-69 in the target population at the end of the period.

Performance of a screening test was assessed using breast cancer detection rates and further assessment rates. Further assessment comprises any additional examination performed until 6 months after screening mammography. Screen-detected cancers comprise all diagnosed breast cancer cases until one year after positive screening. Benign to malignant open biopsy ratio was defined as ratio of the number of women undergoing open biopsy with benign result to the number of women undergoing open biopsy with malignant result. All results were stratified according to the individual screening history of the women: initial or subsequent screening. In order to estimate time-related trends in further assessment rates and detection rates irrespective of changes in age structure and in proportion of initially screened women, standardization \[[@B22]\] was performed. All analyses were performed using Stata/IC 10.1 for Windows \[[@B23]\]. Providers of the utilised data consented with their use for epidemiological research. The study was entirely observational; therefore, no approval from the ethical committee was required.

Results
=======

Breast cancer burden in the Czech Republic
------------------------------------------

The incidence rate of breast cancer has been increasing constantly since the early 1990s (65.5 cases per 100,000 women in 1990 vs. 122.7 in 2007). On the other hand, the mortality rate was stable during the same period (34.2 cases per 100,000 women in 1990 vs. 36.4 in 2007, Figure [2](#F2){ref-type="fig"}). The peak value of breast cancer incidence can be observed in 2003 after the introduction of an organised screening programme and again in 2007 when the growing programme was reinforced by a pilot project for the invitation of yet-unscreened women (see discussion for description). It is clearly visible particularly in newly introduced women aged 70-74 years (Figure [3](#F3){ref-type="fig"}). The continuing rise in incidence after 2002 could be attributed to the screening target population, i.e. women aged 45-69 years. The incidence is stable in younger (30-44 years) and older (75+ years) women.

![**Time trends of breast cancer incidence and mortality rates in the Czech Republic**. Source of data: Czech National Cancer Registry.](1471-2458-11-288-2){#F2}

![**Time trends in age-specific breast cancer incidence rate**. Source of data: Czech National Cancer Registry.](1471-2458-11-288-3){#F3}

The rise in incidence rate after 1990 is visible in all postmenopausal age groups. The most recent growth is reduced in the 70-74 age group, due to detection of tumours at a younger age in the screening programme (Figure [4](#F4){ref-type="fig"}). There is an apparent increase in the proportion of stage I breast cancers which started in the early 1990s and continues after 2002 (Figure [5](#F5){ref-type="fig"}). This is reflected in increase of early breast cancer rates in the 45-69 age groups. During the same period, we can witness slow decrease in advanced cancer rates (stage III+IV, 50.5 cases per 100,000 women in 1990-1994 vs. 38.1 in 2003-2007, Figure [6](#F6){ref-type="fig"}).

![**Comparison of age structure of breast cancer patients groups diagnosed in different time periods**. Source of data: Czech National Cancer Registry.](1471-2458-11-288-4){#F4}

![**Time trends in distribution of clinical stages in newly diagnosed breast cancer cases in the Czech Republic**. Source of data: Czech National Cancer Registry.](1471-2458-11-288-5){#F5}

![**Time trends of breast cancer incidence rates in women aged 45-69 years, according to clinical stage at diagnosis**. Source of data: Czech National Cancer Registry.](1471-2458-11-288-6){#F6}

Results of the organised screening programme
--------------------------------------------

The Czech Breast Cancer Screening Registry includes 2,083,285 records on screening episodes between 2002 and 2008. The 24-month coverage by screening mammography steadily increased over these years (Table [1](#T1){ref-type="table"}). The coverage in the age group of 45-69 year-olds reached 51.2% in 2008. In years 2002-2004, women attended programme screening examination for the first time (initial screening). Since then, the proportion of subsequent screenings has been constantly rising and reached 66% in 2008. The age of women attending screenings is also increasing (Table [2](#T2){ref-type="table"}). Recruitment is less effective in higher age categories, the coverage decreases from 58.0% at age 45-49 to 42.3% at age 65-69. The screening programme was not open to elderly women (aged over 70) free of charge before 2010. They were only invited as a part of the pilot project in 2007-2008 and the coverage is therefore only 14.5% of this age group (Table [3](#T3){ref-type="table"}).

###### 

Performance indicators of the Czech Breast Cancer Screening Programme, according to year of screening, including all age groups (total).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                    Year (screening mammography)                                                               
  ------------------------------------------------------------------------------------------------- ------------------------------ ----------- ----------- ----------- ----------- ----------- -----------
  Number of women screened                                                                          10,055                         212,537     265,217     317,194     340,564     469,299     468,419

    **Estimate of 24 m coverage by examination**\                                                   **0.6%**                       **13.1%**   **27.9%**   **33.8%**   **38.1%**   **44.8%**   **51.2%**
  **(women aged 45-69)**                                                                                                                                                                       

   Number of women with detected breast cancer                                                      48                             1,053       1,250       1,445       1,570       2,542       2,128

    **Breast cancer detection rate**                                                                **4.8**                        **5.0**     **4.7**     **4.6**     **4.6**     **5.4**     **4.5**

    **Standardized ratio (reference year 2008)**                                                    **0.81**                       **0.83**    **0.80**    **0.85**    **0.96**    **0.97**    **1.00**

   Number of women undergoing further assessment                                                    1,768                          46,976      57,925      56,850      53,580      63,415      60,025

    **Further assessment rate**                                                                     **17.6%**                      **22.1%**   **21.8%**   **17.9%**   **15.7%**   **13.5%**   **12.8%**

    **Standardized ratio (reference year 2008)**                                                    **0.90**                       **1.20**    **1.21**    **1.14**    **1.10**    **1.01**    **1.00**

   Number of women recalled for further assessment                                                  557                            12,095      11,725      11,931      10,429      13,977      12,955

    **Recall rate**                                                                                 **5.5%**                       **5.7%**    **4.4%**    **3.8%**    **3.1%**    **3.0%**    **2.8%**

   Women undergoing open biopsy - benign result                                                     21                             504         347         285         194         249         173

   Women undergoing open biopsy - malignant result                                                  43                             867         1,021       1,259       1,347       2,149       1,794

    **Benign to malignant open biopsy ratio**                                                       **0.49**                       **0.58**    **0.34**    **0.23**    **0.14**    **0.12**    **0.10**

   Number of women with detected breast cancer *(cases preceded by neoadjuvant therapy excluded)*   48                             1,031       1,212       1,400       1,522       2,470       2,039

    Advanced cases (TNM II+)                                                                        17                             331         390         440         439         652         525

     **Advanced cases proportion**                                                                  **35.4%**                      **32.1%**   **32.2%**   **31.4%**   **28.8%**   **26.4%**   **25.7%**

    Invasive cases                                                                                  41                             933         1,097       1,283       1,370       2,211       1,831

     **Invasive cases proportion**                                                                  **85.4%**                      **90.5%**   **90.5%**   **91.6%**   **90.0%**   **89.5%**   **89.8%**

     Node-negative invasive cases                                                                   27                             572         700         840         905         1,442       1,218

  **Proportion among invasive**                                                                     **65.9%**                      **61.3%**   **63.8%**   **65.5%**   **66.1%**   **65.2%**   **66.5%**

     Invasive ≤ 10 mm cases                                                                         11                             312         360         460         504         770         651

  **Proportion among invasive**                                                                     **26.8%**                      **33.4%**   **32.8%**   **35.9%**   **36.8%**   **34.8%**   **35.6%**
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Time trends in basic characteristics of the population attending the screening programme.

  Year screened   NUMBER OF WOMEN SCREENED   Proportion subsequent               AGE SCREENED                            
  --------------- -------------------------- ----------------------- ----------- -------------- ------ ---------- ------ ------
  **2002**        10,055                     0                       **0.0%**    45.6           49.2   **53.8**   59.0   66.5
  **2003**        212,514                    23                      **0.0%**    45.7           49.4   **53.9**   59.3   66.7
  **2004**        258,635                    6,582                   **2.5%**    45.4           49.4   **54.2**   59.7   66.9
  **2005**        220,897                    96,297                  **30.4%**   45.5           50.0   **54.9**   60.3   67.1
  **2006**        170,717                    169,847                 **49.9%**   45.5           50.1   **55.1**   60.5   67.2
  **2007**        232,509                    236,790                 **50.5%**   45.3           50.9   **56.9**   63.2   70.6
  **2008**        159,273                    309,146                 **66.0%**   45.3           50.6   **56.1**   61.6   68.0

###### 

Performance indicators of the Czech Breast Cancer Screening Programme, according to age group, women screened in 2008 (total).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                    Age group   Total\      Total\                                                      
                                                                                                                45-69       50-69                                                       
  ------------------------------------------------------------------------------------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  Number of women screened                                                                          95,883      106,232     105,578     90,394      55,427      4,848       453,514     357,631

    **Estimate of 24 m coverage by examination**                                                    **58.0%**   **55.0%**   **51.6%**   **47.5%**   **42.3%**   **14.5%**   **51.2%**   **49.6%**

   Number of women with detected breast cancer                                                      254         374         416         577         409         67          2,030       1,776

    **Breast cancer detection rate**                                                                **2.6**     **3.5**     **3.9**     **6.4**     **7.4**     **13.8**    **4.5**     **5.0**

   Number of women undergoing further assessment                                                    20,881      14,923      10,318      7,174       3,959       409         57,255      36,374

    **Further assessment rate**                                                                     **21.8%**   **14.0%**   **9.8%**    **7.9%**    **7.1%**    **8.4%**    **12.6%**   **10.2%**

   Number of women recalled for further assessment                                                  3,652       2,913       2,421       2,149       1,291       162         12,426      8,774

    **Recall rate**                                                                                 **3.8%**    **2.7%**    **2.3%**    **2.4%**    **2.3%**    **3.3%**    **2.7%**    **2.5%**

   Women undergoing open biopsy - benign result                                                     50          40          27          31          21          1           169         119

   Women undergoing open biopsy - malignant result                                                  211         315         368         481         334         58          1,709       1,498

    **Benign to malignant open biopsy ratio**                                                       **0.24**    **0.13**    **0.07**    **0.06**    **0.06**    **0.02**    **0.10**    **0.08**

   Number of women with detected breast cancer *(cases preceded by neoadjuvant therapy excluded)*   239         352         401         555         399         65          1,946       1,707

    Advanced cases (TNM II+)                                                                        63          98          104         131         95          27          491         428

     **Advanced cases proportion**                                                                  **26.4%**   **27.8%**   **25.9%**   **23.6%**   **23.8%**   **41.5%**   **25.2%**   **25.1%**

    Invasive cases                                                                                  216         315         343         508         360         63          1,742       1,526

     **Invasive cases proportion**                                                                  **90.4%**   **89.5%**   **85.5%**   **91.5%**   **90.2%**   **96.9%**   **89.5%**   **89.4%**

     Node-negative invasive cases                                                                   131         196         238         342         255         38          1,162       1,031

  **Proportion among invasive**                                                                     **60.6%**   **62.2%**   **69.4%**   **67.3%**   **70.8%**   **60.3%**   **66.7%**   **67.6%**

     Invasive ≤ 10 mm cases                                                                         70          110         119         179         146         19          624         554

  **Proportion among invasive**                                                                     **32.4%**   **34.9%**   **34.7%**   **35.2%**   **40.6%**   **30.2%**   **35.8%**   **36.3%**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The crude breast cancer detection rate has been changing a little during first years of the programme (Table [1](#T1){ref-type="table"}). Over years and age subgroups, the detection rate was always higher in initially screened women (Tables [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}) than in subsequently screened women (Tables [6](#T6){ref-type="table"}, [7](#T7){ref-type="table"}). The detection rate increases with age in initial (3.1-15.1 detected cases per 1,000 women screened, Table [5](#T5){ref-type="table"}) and subsequent (2.1-11.7 detected cases per 1,000 women screened, Table [7](#T7){ref-type="table"}) screenings. Bearing the rapidly changing population structure in mind, it is therefore more informative to study development of age-specific rates in initial and subsequent screenings (Figure [7](#F7){ref-type="fig"}) or summarize them using a standardized rate ratio (Table [1](#T1){ref-type="table"}). Both show evidence for constantly improving detection rates after the organisation of the screening programme.

###### 

Performance indicators of the Czech Breast Cancer Screening Programme, according to year of screening, including all age groups (initial screening).

                                                                                                    Year (screening mammography)                                                               
  ------------------------------------------------------------------------------------------------- ------------------------------ ----------- ----------- ----------- ----------- ----------- -----------
  Number of women screened                                                                          10,055                         212,514     258,635     220,897     170,717     232,509     159,273
   Number of women with detected breast cancer                                                      48                             1,053       1,220       1,153       935         1,662       974
    **Breast cancer detection rate**                                                                **4.8**                        **5.0**     **4.7**     **5.2**     **5.5**     **7.1**     **6.1**
   Number of women undergoing further assessment                                                    1,768                          46,973      56,961      44,919      33,135      39,921      30,239
    **Further assessment rate**                                                                     **17.6%**                      **22.1%**   **22.0%**   **20.3%**   **19.4%**   **17.2%**   **19.0%**
   Number of women recalled for further assessment                                                  557                            12,095      11,535      9,735       6,496       8,888       6,246
    **Recall rate**                                                                                 **5.5%**                       **5.7%**    **4.5%**    **4.4%**    **3.8%**    **3.8%**    **3.9%**
   Women undergoing open biopsy - benign result                                                     21                             504         343         226         135         166         90
   Women undergoing open biopsy - malignant result                                                  43                             867         992         994         787         1,382       784
    **Benign to malignant open biopsy ratio**                                                       **0.49**                       **0.58**    **0.35**    **0.23**    **0.17**    **0.12**    **0.11**
   Number of women with detected breast cancer *(cases preceded by neoadjuvant therapy excluded)*   48                             1,031       1,182       1,116       905         1,610       924
    Advanced cases (TNM II+)                                                                        17                             331         384         367         284         465         277
     **Advanced cases proportion**                                                                  **35.4%**                      **32.1%**   **32.5%**   **32.9%**   **31.4%**   **28.9%**   **30.0%**
    Invasive cases                                                                                  41                             933         1,072       1,023       823         1,459       850
     **Invasive cases proportion**                                                                  **85.4%**                      **90.5%**   **90.7%**   **91.7%**   **90.9%**   **90.6%**   **92.0%**
     Node-negative invasive cases                                                                   27                             572         682         644         525         909         535
  **Proportion among invasive**                                                                     **65.9%**                      **61.3%**   **63.6%**   **63.0%**   **63.8%**   **62.3%**   **62.9%**
     Invasive ≤ 10 mm cases                                                                         11                             312         350         348         288         441         275
  **Proportion among invasive**                                                                     **26.8%**                      **33.4%**   **32.6%**   **34.0%**   **35.0%**   **30.2%**   **32.4%**

###### 

Performance indicators of the Czech Breast Cancer Screening Programme, according to age group, women screened in 2008 (initial screening).

  ----------------------------------------------------------------------------------------------------------------------------------------------------
                                                       Age group   Total\      Total\                                                      
                                                                   45-69       50-69                                                       
  ---------------------------------------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  Number of women screened                             54,495      26,214      26,694      24,452      16,067      3,047       147,922     93,427

   Number of women with detected breast cancer         169         126         150         245         211         46          901         732

    **Breast cancer detection rate**                   **3.1**     **4.8**     **5.6**     **10.0**    **13.1**    **15.1**    **6.1**     **7.8**

   Number of women undergoing further assessment       14,188      5,097       3,749       2,998       1,808       306         27,840      13,652

    **Further assessment rate**                        **26.0%**   **19.4%**   **14.0%**   **12.3%**   **11.3%**   **10.0%**   **18.8%**   **14.6%**

   Number of women recalled for further assessment     2,430       1,007       845         901         626         124         5,809       3,379

    **Recall rate**                                    **4.5%**    **3.8%**    **3.2%**    **3.7%**    **3.9%**    **4.1%**    **3.9%**    **3.6%**

   Women undergoing open biopsy - benign result        35          18          8           14          11          1           86          51

   Women undergoing open biopsy - malignant result     135         101         132         194         161         38          723         588

    **Benign to malignant open biopsy ratio**          **0.26**    **0.18**    **0.06**    **0.07**    **0.07**    **0.03**    **0.12**    **0.09**

   Number of women with detected breast cancer\        159         115         144         233         205         44          856         697
  *(cases preceded by neoadjuvant therapy excluded)*                                                                                       

    Advanced cases (TNM II+)                           47          34          45          72          55          19          253         206

     **Advanced cases proportion**                     **29.6%**   **29.6%**   **31.3%**   **30.9%**   **26.8%**   **43.2%**   **29.6%**   **29.6%**

    Invasive cases                                     146         106         129         216         189         42          786         640

     **Invasive cases proportion**                     **91.8%**   **92.2%**   **89.6%**   **92.7%**   **92.2%**   **95.5%**   **91.8%**   **91.8%**

     Node-negative invasive cases                      83          68          85          136         124         24          496         413

  **Proportion among invasive**                        **56.8%**   **64.2%**   **65.9%**   **63.0%**   **65.6%**   **57.1%**   **63.1%**   **64.5%**

     Invasive ≤ 10 mm cases                            47          32          42          64          73          10          258         211

  **Proportion among invasive**                        **32.2%**   **30.2%**   **32.6%**   **29.6%**   **38.6%**   **23.8%**   **32.8%**   **33.0%**
  ----------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Performance indicators of the Czech Breast Cancer Screening Programme, according to year of screening, including all age groups (subsequent screening).

                                                                                                    Year (screening mammography)                                       
  ------------------------------------------------------------------------------------------------- ------------------------------ ----------- ----------- ----------- -----------
  Number of women screened                                                                          6,582                          96,297      169,847     236,790     309,146
   Number of women with detected breast cancer                                                      30                             292         635         880         1,154
    **Breast cancer detection rate**                                                                **4.6**                        **3.0**     **3.7**     **3.7**     **3.7**
   Number of women undergoing further assessment                                                    964                            11,931      20,445      23,494      29,786
    **Further assessment rate**                                                                     **14.6%**                      **12.4%**   **12.0%**   **9.9%**    **9.6%**
   Number of women recalled for further assessment                                                  190                            2,196       3,933       5,089       6,709
    **Recall rate**                                                                                 **2.9%**                       **2.3%**    **2.3%**    **2.1%**    **2.2%**
   Women undergoing open biopsy - benign result                                                     4                              59          59          83          83
   Women undergoing open biopsy - malignant result                                                  29                             265         560         767         1,010
    **Benign to malignant open biopsy ratio**                                                       **0.14**                       **0.22**    **0.11**    **0.11**    **0.08**
   Number of women with detected breast cancer *(cases preceded by neoadjuvant therapy excluded)*   30                             284         617         860         1,115
    Advanced cases (TNM II+)                                                                        6                              73          155         187         248
     **Advanced cases proportion**                                                                  **20.0%**                      **25.7%**   **25.1%**   **21.7%**   **22.2%**
    Invasive cases                                                                                  25                             260         547         752         981
     **Invasive cases proportion**                                                                  **83.3%**                      **91.5%**   **88.7%**   **87.4%**   **88.0%**
     Node-negative invasive cases                                                                   18                             196         380         533         683
  **Proportion among invasive**                                                                     **72.0%**                      **75.4%**   **69.5%**   **70.9%**   **69.6%**
     Invasive ≤ 10 mm cases                                                                         10                             112         216         329         376
  **Proportion among invasive**                                                                     **40.0%**                      **43.1%**   **39.5%**   **43.8%**   **38.3%**

###### 

Performance indicators of the Czech Breast Cancer Screening Programme, according to age group, women screened in 2008 (subsequent screening).

  -----------------------------------------------------------------------------------------------------------------------------------------------------
                                                       Age group   Total\      Total\                                                       
                                                                   45-69       50-69                                                        
  ---------------------------------------------------- ----------- ----------- ----------- ----------- ----------- ------------ ----------- -----------
  Number of women screened                             41,388      80,018      78,884      65,942      39,360      1,801        305,592     264,204

   Number of women with detected breast cancer         85          248         266         332         198         21           1,129       1,044

    **Breast cancer detection rate**                   **2.1**     **3.1**     **3.4**     **5.0**     **5.0**     **11.7**     **3.7**     **4.0**

   Number of women undergoing further assessment       6,693       9,826       6,569       4,176       2,151       103          29,415      22,722

    **Further assessment rate**                        **16.2%**   **12.3%**   **8.3%**    **6.3%**    **5.5%**    **5.7%**     **9.6%**    **8.6%**

   Number of women recalled for further assessment     1,222       1,906       1,576       1,248       665         38           6,617       5,395

    **Recall rate**                                    **3.0%**    **2.4%**    **2.0%**    **1.9%**    **1.7%**    **2.1%**     **2.2%**    **2.0%**

   Women undergoing open biopsy - benign result        15          22          19          17          10          0            83          68

   Women undergoing open biopsy - malignant result     76          214         236         287         173         20           986         910

    **Benign to malignant open biopsy ratio**          **0.20**    **0.10**    **0.08**    **0.06**    **0.06**    **0.00**     **0.08**    **0.07**

   Number of women with detected breast cancer\        80          237         257         322         194         21           1,090       1,010
  *(cases preceded by neoadjuvant therapy excluded)*                                                                                        

    Advanced cases (TNM II+)                           16          64          59          59          40          8            238         222

     **Advanced cases proportion**                     **20.0%**   **27.0%**   **23.0%**   **18.3%**   **20.6%**   **38.1%**    **21.8%**   **22.0%**

    Invasive cases                                     70          209         214         292         171         21           956         886

     **Invasive cases proportion**                     **87.5%**   **88.2%**   **83.3%**   **90.7%**   **88.1%**   **100.0%**   **87.7%**   **87.7%**

     Node-negative invasive cases                      48          128         153         206         131         14           666         618

  **Proportion among invasive**                        **68.6%**   **61.2%**   **71.5%**   **70.5%**   **76.6%**   **66.7%**    **69.7%**   **69.8%**

     Invasive ≤ 10 mm cases                            23          78          77          115         73          9            366         343

  **Proportion among invasive**                        **32.9%**   **37.3%**   **36.0%**   **39.4%**   **42.7%**   **42.9%**    **38.3%**   **38.7%**
  -----------------------------------------------------------------------------------------------------------------------------------------------------

![**Breast cancer detection rate: age-specific comparison of time periods**.](1471-2458-11-288-7){#F7}

The further assessment rate has been decreasing since 2003 to 12.8% in 2008 (Table [1](#T1){ref-type="table"}). This indicator is also subject to trends in age structure and the proportion of subsequent examinations. This rate decreases with age in initial (26.0%-10.0%, Table [5](#T5){ref-type="table"}) and subsequent (16.2%-5.7%, Table [7](#T7){ref-type="table"}) screenings, being larger in initial screening. Improvement (i.e. decrease) in further assessment rates is clear from both age-specific (Figure [8](#F8){ref-type="fig"}) and standardized indicators (Table [1](#T1){ref-type="table"}). Trends in the recall rate are very similar to those in the further assessment rate. Only about 20-30% of women with positive results of screening are being recalled back to the screening centre. The rest of the women undergo further assessment on the day of the screening visit. The benign to malignant open biopsy ratio is also constantly improving (0.49 in 2002 vs. 0.10 in 2008). The ratio is similar in initially and subsequently screened women. The youngest age groups experience a slightly increased ratio (Tables [5](#T5){ref-type="table"}, [7](#T7){ref-type="table"}).

![**Further assessment rate: age-specific comparison of time periods**.](1471-2458-11-288-8){#F8}

About 30% of detected breast cancer cases are advanced (TNM stage II+, i.e. involvement of lymph nodes and/or distant metastases) in initial screenings, and this proportion decreases to about 20% in subsequent screenings (Tables [4](#T4){ref-type="table"}, [6](#T6){ref-type="table"}). About 90% of detected cases are invasive in both initial and subsequent screenings. Of these, 60-70% of the findings are without involvement of lymph nodes (this proportion is higher in subsequent screenings). The primary tumour in about 30-40% of invasive cases is less than 10 mm in diameter (this proportion is higher in subsequent screenings).

Discussion
==========

A recent study \[[@B9]\] reviewed current evidence on the effectiveness of mammography screening in real populations. The authors identified reports from eight European countries, where mammography screening lead to an eventual decrease in breast cancer mortality. National programmes included Finland \[[@B24]\], Iceland \[[@B25]\], the Netherlands \[[@B26]\] and the United Kingdom \[[@B27]\]. Regionally organised programmes included Denmark \[[@B28]\], Italy \[[@B29]\], Spain \[[@B30]\] and Sweden \[[@B31],[@B32]\]. All of these countries implemented organised screening programmes in the 1980s or early 1990s. Organised screening policies in these countries include the specification of covered age groups, screening interval and detection methods \[[@B7]\]. Programmes include quality assurance systems \[[@B33]\] that utilise data on screening process and also have access to cancer registry data \[[@B34]\].

The CBCSP has been implemented to comprise such organisational aspects, as recommended by the IARC working group. We made comprehensive use of three valuable data sources (cancer registry, cancer screening registry, and the data warehouse of healthcare payers) to continuously monitor the success of the programme. The following discussion compares observed values of early performance indicators with published results and European Guidelines targets \[[@B11]\], which are based on the results of randomized trials and successful screening programmes.

Epidemiology
------------

In addition to the performance monitoring, the Czech screening programme is supported with highly representative epidemiology cancer registry covering the whole population since 1977. Breast cancer incidence has been rising steadily since 1980s. However, further increase in mortality has been arrested after 1995, similarly to other member states of the European Union \[[@B3]\]. The stabilized breast cancer mortality in the Czech Republic can be at least partially attributed to the improving stage distribution of newly diagnosed breast cancer cases and mild decrease in rate of advanced tumours. Nevertheless, part of the increase in early tumours rate is attributable to overdiagnosis - screen-detected cancers that would not have surfaced clinically during the woman\'s lifetime \[[@B35]\]. Estimate of the proportion of overdiagnosed tumours ranges to over 50% \[[@B36]\]; however, most of the estimates vary from 1% to 10% \[[@B6]\]. Very gradual expansion of opportunistic and organised screening does not yet allow us to estimate extent of overdiagnosis precisely using epidemiology data; therefore, we have concentrated on assessment of early performance indicators. As their values of detection rates and DCIS proportion comply with European Guidelines targets quite well (see bellow), we do not assume overdiagnosis to markedly excess values seen in clinical and epidemiological studies abroad.

Coverage
--------

The current Czech system of recruitment through GPs or gynaecologists, reinforced by media campaigns and recall for subsequent screenings by screening centres was able to achieve a modest coverage of 50%. The advantage of this setup is the primary care physician\'s full knowledge of the patient\'s medical history and preferences, which enables the proper tailoring of an individual preventive strategy. Nevertheless, participation rates in successful population-based programmes approach the European Guidelines target of 70% (e.g. Spain \[[@B37]\], United Kingdom \[[@B38]\], Denmark \[[@B39]\]), or even exceed them (Finland \[[@B40]\]). However, the invitation may also fail to achieve the stated target (e.g. decentralized invitation in Hungary \[[@B16]\], invitation without appointment in Luxembourg \[[@B41]\]) - it is therefore necessary to properly plan, implement and monitor the invitation process.

Pilot project
-------------

That is why in 2007-2008 a pilot project of centralised invitation of non-attending women was undertaken. The project was carried out by the General Health Insurance Company (GHIC). GHIC is the principal provider of health insurance in the Czech Republic, with more than 6.5 million clients (about two thirds of the Czech population). A total number of 598,637 women aged between 45 and 74 years were invited for screening mammography (the invited women had not undergone mammography examination during the last three years). The women invited to the pilot project were screened between July 2007 and February 2008. Overall, 107,264 women (i.e., 18% of those invited) were screened at 60 mammography screening facilities. As regards the target population (45-69 years), 491,294 women were invited and 16.4% of them were screened. Participation rate was higher in older women (24.7%).

Despite the relatively low participation rate in the project itself, the project helped to substantially increase coverage in the target population (from 38.1% in 2006 to 51.2% in 2008), especially in elder women. Furthermore, the pilot project also invited women aged 70-74 and the outcomes of the screening in this group are visible in the epidemiology data. The pilot project confirmed a high sensitivity and specificity of mammography in these elderly groups and led to the extension of the age groups targeted by the Czech screening programme in 2010.

Opportunistic activities
------------------------

Screening activities occurring outside the programme or before its inception are referred to as \'opportunistic\' screening. Opportunistic screening may fail to exploit the full potential of mammography to prevent deaths from breast cancer \[[@B42]\]. A possible explanation includes less sensitivity \[[@B43]\] and subsequently less-favourable prognostic features of detected tumours \[[@B44]\]. It is less cost-effective, mainly due to higher cost of diagnostic mammography and overuse of additional imaging in an unorganized setting \[[@B45],[@B46]\]. Dissemination of organised mammography screening can increase programme coverage \[[@B17]\] and also attract more disadvantaged women \[[@B47]\]. It is therefore advisable to promote the highest level of organisation possible, with close monitoring of performance indicators \[[@B14]\].

Intensified nationwide organisation led to an increase in opportunistic mammography activities in Hungary \[[@B17]\]. Yet Jensen \[[@B48]\] concluded that, in Denmark, women not attending an organised programme did not seek the service elsewhere and proportion of women screened outside the programme was 1-4% in Danish counties. According to monitoring performed by the Czech healthcare payers, the non-programme screening was quite prevalent in the Czech Republic before the onset of the organized programme. In 2002, the proportion of women undergoing non-programme examination was over 15% and approached 25% in some regions. In the following years, the overall proportion has been decreasing below 10%; however, it still remains high in some regions.

Sensitivity of the programme
----------------------------

Important early indirect measures of test and programme sensitivity include detection rate, stage distribution of detected cancers and incidence of interval cancers \[[@B11],[@B14]\].

The presence of opportunistic screening and gradual recruitment into organised screening make it difficult to estimate incidence rates expected in the target population in the absence of screening (background incidence), which is necessary to interpret detection and interval cancer rates. Anyway, a rough estimate could be acquired by averaging pre-programme breast cancer rates. The resulting ratio of detection rate to background incidence rate in initial screening for women aged 50-69 years is 4.1, which is in accordance with European Guidelines and similar to values observed in European pilot projects \[[@B49]\].

Easily observable measures of stage distribution are defined in European Guidelines. The proportion of advanced tumours and the proportion of small invasive tumours achieved the desirable levels given by European Guidelines. On the other hand, the proportion of node-negative invasive tumours keeps staying below acceptable level. However, modern pathology techniques may lead to increased detection of node metastases of lesser clinical significance \[[@B50],[@B51]\] and targets might need to be restated in light of the new epidemiological data.

Precise estimation of interval cancer rates has not yet been possible in the Czech screening, due to the non-existing direct individual link between the cancer registry and the cancer screening registry. Prediction of the rate is possible, e.g. using the Markov model \[[@B52]\], however, we don\'t consider this approach for continuous monitoring of performance indicators.

Safety and efficiency of the programme
--------------------------------------

A specific feature of the CBCSP is one-day diagnostics. Providing final results of a screening examination to the women during the screening visit definitely prevents a great amount of adverse psychological consequences drawn by the screening programme \[[@B53]\] and provides a sufficient level comfort. Yet, it might be quite demanding for the staff of the screening centres and might increase the further assessment rate, because the women are readily available at the screening centre during the mammogram assessment. Indeed, despite the continuous decrease in time, further assessment remains 2-3 times higher than in Western and Northern European countries \[[@B54]\]. Recall rates are nevertheless similar, as only some of women with further assessment are actually recalled back to the screening centre.

The high positive predictive value of further assessment is provided by the successful adoption of preoperative diagnostics with core biopsy. This part of the screening process is reflected by a benign to malignant open biopsy ratio, one of the key indicators in the European Guidelines. Results in the CBCSP achieved the desirable target in the Guidelines and became fully comparable to long operating population-based screening programmes, e.g. in Finland and Italy \[[@B40],[@B55]\].

Conclusions
===========

The transformation from opportunistic prevention to an organised programme facilitated continuous improvement in the quality of offered mammography screening examinations. Most performance indicators reach targets set by European Guidelines and observed in successful population-based programmes around Europe. This promises effectiveness, safety and efficiency similar to randomized clinical trials, which justifies the enormous investment into programme initiation and operation. The important task now is to implement addressed invitations to the screenings and to institute a system for monitoring the impact of cancer screening on population epidemiology, including examination of the possible risk of overdiagnosis.
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